<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03636932</url>
  </required_header>
  <id_info>
    <org_study_id>2017-71</org_study_id>
    <secondary_id>2018-003232-80</secondary_id>
    <nct_id>NCT03636932</nct_id>
  </id_info>
  <brief_title>RENACTIF: Reduction of the Thrombotic Phenotype in Renal Insufficiency With N-AcetylCysteine</brief_title>
  <acronym>RENACTIF</acronym>
  <official_title>RENACTIF: Reduction of the Thrombotic Phenotype in Renal Insufficiency With N-AcetylCysteine A Randomized, Double-blind, Placebo-controlled, Cross-over Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic Kidney Disease (CKD) is a known risk factor of cardiovascular morbidity and&#xD;
      mortality.&#xD;
&#xD;
      In CKD, decline of renal function results in the accumulation of uremic toxins in blood and&#xD;
      tissue, such as Indoxyl Sulfate (IS). IS plasma level is predictive of mortality and&#xD;
      cardiovascular disease (CVD). Patients with CKD have increased oxidative stress and&#xD;
      circulating tissue factor (TF) levels. In vitro, IS induces an inflammatory, pro-oxidative&#xD;
      and pro-coagulant phenotype on endothelial cells and activates TF. N-acetylcysteine (NAC)&#xD;
      protects endothelial cells from the effects of IS. NAC reduces oxidative stress and&#xD;
      production of activated TF. A prospective study evaluating an oral NAC treatment versus&#xD;
      placebo in chronic hemodialysis patients showed a better cardiovascular outcome but the&#xD;
      physiopathology was unclear.&#xD;
&#xD;
      The hypothesis is that NAC reduces cardiovascular risk by its effect on uremic toxin-induced&#xD;
      pro-coagulant TF production.&#xD;
&#xD;
      The primary objective is to compare the effect of NAC intravenously administered at each&#xD;
      dialysis session (2gram on 3 dialysis sessions per week) to placebo on circulating TF levels&#xD;
      in patients with CKD on chronic hemodialysis after 4 weeks of treatment. The objective is to&#xD;
      show a 33% decrease in circulating tissue factor (TF) levels in the NAC group compared to the&#xD;
      control group.&#xD;
&#xD;
      It is a randomized, double-blind, placebo-controlled crossover trial that includes chronic&#xD;
      hemodialysis patients from La Conception Hospital (AP-HM) in Marseilles, France. This is an&#xD;
      interventional biomedical research project.&#xD;
&#xD;
      20 patients will be included in each group and will receive during 4 weeks intravenous&#xD;
      injection.&#xD;
&#xD;
      This study will give a pathophysiological rationale for the use of NAC to reduce thrombotic&#xD;
      and cardiovascular risk in patients with CKD. This step will provide the rationale for a&#xD;
      clinical trial to reduce the occurrence of major cardiovascular events with IV NAC in&#xD;
      hemodialysis (HD) patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">April 29, 2019</start_date>
  <completion_date type="Anticipated">May 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>compare the effect of N-acetylcysteine (NAC) intravenously administered</measure>
    <time_frame>12 months</time_frame>
    <description>show a 33% decrease in circulating tissue factor levels in the N-acetylcysteine (NAC) group</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Chronic Kidney Diseases</condition>
  <arm_group>
    <arm_group_label>N-acetylcysteine (NAC) group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetylcysteine (NAC)</intervention_name>
    <description>Intravenous injection of 2 gram of N-acetylcysteine (NAC) during 4 weeks, 3 times per week during the first three hours of dialysis.</description>
    <arm_group_label>N-acetylcysteine (NAC) group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous injection of 2 gram of Placebo during 4 weeks, 3 times per week during the first three hours of dialysis.</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>Circulating tissue factor assay</description>
    <arm_group_label>N-acetylcysteine (NAC) group</arm_group_label>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>The test of pro-coagulant activity of the tissue factor</description>
    <arm_group_label>N-acetylcysteine (NAC) group</arm_group_label>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hemodialysis patients regardless of the etiology of their renal insufficiency for more&#xD;
             than 3 months on a cycle of 3 sessions per week&#xD;
&#xD;
          -  Hemodialysis patients at least 4 hours per dialysis session&#xD;
&#xD;
          -  Patients with a weight of more than 40 kilogram&#xD;
&#xD;
          -  Patients capable of giving informed consent, agreeing to participate in the study and&#xD;
             having signed a consent&#xD;
&#xD;
          -  Patient able to understand a written questionnaire&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Persons deprived of their liberty or hospitalized without consent&#xD;
&#xD;
          -  Majors under legal protection or unable to express their consent&#xD;
&#xD;
          -  Possibility of recovery of renal function (scleroderma for example)&#xD;
&#xD;
          -  Chronic progressive infection that may affect their thrombotic risk&#xD;
&#xD;
          -  Patients under 40 kilogram&#xD;
&#xD;
          -  Patient taking oral anticoagulants&#xD;
&#xD;
          -  Patient with a known allergy to the active molecule or to any of its excipients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Olivier ARNAUD, Director</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique Hôpitaux de Marseille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marion SALLEE, PH</last_name>
    <phone>491383042</phone>
    <phone_ext>+33</phone_ext>
    <email>marion.sallee@ap-hm.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assistance Publique Hôpitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13354</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marion SALLEE, PH</last_name>
      <phone>491383042</phone>
      <phone_ext>+33</phone_ext>
      <email>marion.sallee@ap-hm.fr</email>
    </contact>
    <contact_backup>
      <last_name>PH</last_name>
    </contact_backup>
    <investigator>
      <last_name>Marion SALLEE, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>August 16, 2018</study_first_submitted>
  <study_first_submitted_qc>August 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2018</study_first_posted>
  <last_update_submitted>April 29, 2019</last_update_submitted>
  <last_update_submitted_qc>April 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

